[go: up one dir, main page]

WO1999004026A3 - Vecteurs lentiviraux - Google Patents

Vecteurs lentiviraux Download PDF

Info

Publication number
WO1999004026A3
WO1999004026A3 PCT/US1998/014996 US9814996W WO9904026A3 WO 1999004026 A3 WO1999004026 A3 WO 1999004026A3 US 9814996 W US9814996 W US 9814996W WO 9904026 A3 WO9904026 A3 WO 9904026A3
Authority
WO
WIPO (PCT)
Prior art keywords
lentiviral
lentiviral vectors
ltr
lentiviral vector
rre
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/014996
Other languages
English (en)
Other versions
WO1999004026A2 (fr
Inventor
Shin-Tai Chen
Mehdi Gasmi
Jiing Kuan Yee
Douglas J Jolly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU85762/98A priority Critical patent/AU8576298A/en
Priority to JP2000503232A priority patent/JP2001510053A/ja
Priority to EP98936923A priority patent/EP1003894A2/fr
Priority to CA002296319A priority patent/CA2296319A1/fr
Publication of WO1999004026A2 publication Critical patent/WO1999004026A2/fr
Publication of WO1999004026A3 publication Critical patent/WO1999004026A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des vecteurs lentiviraux comprenant une longue répétition terminale (LTR) lentivirale 5', un site de fixation d'ARNt, un signal d'encapsidation, un promoteur fixé de manière fonctionnelle à un ou à plusieurs gènes d'intérêt, une origine de la synthèse du second brin d'ADN et une LTR lentivirale 3', le vecteur lentiviral contenant un élément de transport nucléaire qui n'est pas RRE (site de liaison de la protéine Rex). L'invention concerne également des cassettes d'expression et des lignées de cellules d'encapsidation permettant de produire des particules de vecteurs lentiviraux.
PCT/US1998/014996 1997-07-18 1998-07-20 Vecteurs lentiviraux Ceased WO1999004026A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU85762/98A AU8576298A (en) 1997-07-18 1998-07-20 Lentiviral vectors
JP2000503232A JP2001510053A (ja) 1997-07-18 1998-07-20 レンチウイルスベクター
EP98936923A EP1003894A2 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux
CA002296319A CA2296319A1 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5306697P 1997-07-18 1997-07-18
US60/053,066 1997-07-18

Publications (2)

Publication Number Publication Date
WO1999004026A2 WO1999004026A2 (fr) 1999-01-28
WO1999004026A3 true WO1999004026A3 (fr) 1999-04-08

Family

ID=21981716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014996 Ceased WO1999004026A2 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux

Country Status (5)

Country Link
EP (1) EP1003894A2 (fr)
JP (1) JP2001510053A (fr)
AU (1) AU8576298A (fr)
CA (1) CA2296319A1 (fr)
WO (1) WO1999004026A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949424B (zh) * 2015-03-20 2022-03-01 天普大学-联邦高等教育系统 Tat诱导的基于crispr/核酸内切酶的基因编辑

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
WO2000000600A2 (fr) * 1997-09-22 2000-01-06 Chang Lung Ji Vecteurs lentiviraux
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2000062735A2 (fr) 1999-04-15 2000-10-26 Pro-Virus, Inc. Traitement de neoplasmes avec des virus
JP2002508338A (ja) * 1997-12-12 2002-03-19 ナルディニ，ルイジ レンチウィルスベクターの治療使用
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318575A1 (fr) * 1998-01-16 1999-07-22 Chiron Corporation Vecteurs de therapie genique du virus de l'immunodeficience feline
AU5323599A (en) 1998-07-29 2000-02-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of constitutive transport elements for host range control
AU4096100A (en) * 1999-04-23 2000-11-10 Centre For Translational Research In Cancer Pseudotyped retroviral vector for gene therapy of cancer
EP1171624B1 (fr) * 1999-04-29 2007-07-25 Cell Genesys, Inc. Procede et moyens de production de vecteurs lentiviraux recombinants surs et a titre eleve
US6730297B1 (en) * 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
JP2003501066A (ja) * 1999-06-09 2003-01-14 シンジエニツクス・リミテツド Ｓｉｖベースのパッケージング欠損ベクター
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AU2001278430A1 (en) * 2000-05-22 2001-12-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Systemic and cardiovascular transduction with lentiviral vectors
WO2001092506A1 (fr) * 2000-05-30 2001-12-06 University Of Rochester Systemes de vecteurs lentiviraux derives de virus d'immunodeficience simienne (siv)
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
CA2456169C (fr) 2001-08-02 2012-05-22 Didier Trono Procedes et compositions relatifs a des systemes production ameliores de vecteurs lentiviraux
CA2462628C (fr) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Vecteurs lentiviraux a expression reduite
US7582614B2 (en) 2003-03-07 2009-09-01 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
CA2537953A1 (fr) * 2003-09-09 2005-03-17 Virxsys Corporation Approches a base de vecteurs de lentivirus permettant de generer une reponse immunitaire au virus de l'immunodeficience humaine
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CA2600675C (fr) 2005-03-07 2015-12-15 Robarts Research Institute Combinaison du virus du myxome et de la rapamycine utilisee dans un traitement therapeutique
EP3031923A1 (fr) * 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
AU2016235421A1 (en) * 2015-03-20 2017-10-12 Bluebird Bio, Inc. Vector formulations
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
EP3607072A4 (fr) * 2017-04-03 2021-01-06 American Gene Technologies International Inc. Compositions et méthodes de traitement de la phénylcétonurie
EP3648776A4 (fr) 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles
EP3784281A4 (fr) 2018-04-27 2022-02-16 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Thérapie génique in vivo faisant appel à l'administration d'une construction de gène lentiviral
CN112513072A (zh) 2018-04-27 2021-03-16 威斯康星州医药大学股份有限公司 慢病毒载体转化的t-rapa细胞在改善溶酶体贮积症中的应用
CN117467019A (zh) * 2018-05-18 2024-01-30 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用
US20210348192A1 (en) * 2018-09-20 2021-11-11 National University Corporation Tokyo Medical And Dental University Method for increasing lentiviral vector production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031602A1 (fr) * 1995-04-01 1996-10-10 Oxford Biomedica (Uk) Limited Vecteurs retroviraux
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
WO1997012622A1 (fr) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division
WO1997020052A1 (fr) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Vih recombine, cellules d'encapsidation modifiees et methode de traitement du syndrome d'immunodeficience acquise

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
WO1996031602A1 (fr) * 1995-04-01 1996-10-10 Oxford Biomedica (Uk) Limited Vecteurs retroviraux
WO1997012622A1 (fr) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division
WO1997020052A1 (fr) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Vih recombine, cellules d'encapsidation modifiees et methode de traitement du syndrome d'immunodeficience acquise

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENDER M. A. ET AL.: "EVIDENCE THAT THE PACKAGING SIGNAL OF MOLONEY MURINE LEUKEMIA VIRUS EXTENDS INTO THE GAG REGION", JOURNAL OF VIROLOGY, vol. 61, no. 5, 19 May 1987 (1987-05-19), pages 1639 - 1646, XP002036903 *
BRAY M. ET AL.: "A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type I expression and replication Rev-independent.", PROC. NATL. ACAD. SCI. USA, vol. 91, 1994 - 1256, pages 1260, XP002092484 *
HUANG J. AND LIANG T. J.: "A novel hepatitis B virus (HBV) genetic element with Rev response element-like properties that is essential for expression of HBV gene products.", MOLECULAR AND CELLULAR BIOLOGY, vol. 13, no. 12, 1993, pages 7476 - 7486, XP000676652 *
LEVINE F. ET AL.: "Efficient gene expression in mammalian cells from a dicistronic transcriptional unit in an improved retroviral vector.", GENE, vol. 108, 1991, pages 167 - 174, XP002092486 *
MORGAN R. A. ET AL: "RETROVIRAL VECTORS CONTAINING PUTATIVE INTERNAL RIBOSOME ENTRY SITES: DEVELOPMENT OF A POLYCISTRONIC GENE TRANSFER SYSTEM AND APPLICATIONS TO HUMAN GENE THERAPY", NUCLEIC ACIDS RESEARCH, vol. 20, no. 6, 1992, pages 1293 - 1299, XP002037514 *
NALDINI L. ET AL.: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR", SCIENCE, vol. 272, no. 5259, 12 April 1996 (1996-04-12), pages 263 - 267, XP000583652 *
ORY D. S. ET AL.: "A STABLE HUMAN-DERIVED PACKAGING CELL LINE FOR PRODUCTION OF HIGH TITER RETROVIRUS/VESICULAR STOMATITIS VIRUS G PSEUDOTYPES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, October 1996 (1996-10-01), pages 11400 - 11406, XP002030784 *
SRINIVASAKUMAR N. ET AL.: "The effect of viral regulatory protein expression on gene delivery by human immundeficiency virus type I vectors produced in stable packaging cell lines.", JOURNAL OF VIROLOGY, vol. 71, no. 8, August 1997 (1997-08-01), pages 5841 - 5848, XP002092487 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949424B (zh) * 2015-03-20 2022-03-01 天普大学-联邦高等教育系统 Tat诱导的基于crispr/核酸内切酶的基因编辑

Also Published As

Publication number Publication date
CA2296319A1 (fr) 1999-01-28
JP2001510053A (ja) 2001-07-31
AU8576298A (en) 1999-02-10
WO1999004026A2 (fr) 1999-01-28
EP1003894A2 (fr) 2000-05-31

Similar Documents

Publication Publication Date Title
WO1999004026A3 (fr) Vecteurs lentiviraux
WO1995030763A3 (fr) Vecteurs retroviraux a taux de recombinaison reduit
AU2998597A (en) Crossless retroviral vectors
EP1285967A3 (fr) Lignée cellulaire humaine pour l'empaquetage des rétrovirus
AU4951293A (en) Synthesis of manganese bleach catalyst
WO2001039722A3 (fr) Nouvelle molecule immunoregulatrice b7-h1,
CA2170509A1 (fr) Adn codant le recepteur ep2 de la prostaglandine
CA2165954A1 (fr) Recepteur fp de la prostaglandine et adn codant ce recepteur
WO2000000600A3 (fr) Vecteurs lentiviraux
CA2211204A1 (fr) Recepteur dp de prostaglandine
ZA966711B (en) Chemical synthesis.
AU574715B2 (en) Non flammable aerosol propellant microemulsion
AU1998297A (en) Nucleic acid constructs containing genes encoding transport signals
AU6139699A (en) Packaging cell lines for hiv-derived retroviral vector particles
AU2352095A (en) 7-fluoro-2, 3-didehydrosialic acid and intermediate for synthesis thereof
AU697289B2 (en) Photoprotective cosmetic compositions containing TIO2 nanopigments and an acylamino acid
AU4766596A (en) Ob gene product antibodies
WO1997008190A3 (fr) Composes
AU7567298A (en) (mus dunni) endogenous retroviral packaging cell lines
AU4261797A (en) Retroviral vectors capable of transducing non-dividing cells
WO1995017418A3 (fr) NOUVEAUX INTERMEDIAIRES POUR LA SYNTHESE D'AMIDES DE L-ASPARTYL-D-α-AMINOALCANOYL-(S)-N-α-ALKYLBENZYLE UTILES EN TANT QU'EDULCORANTS ARTIFICIELS
CA2306634A1 (fr) Lignees de cellules d'encapsidation en suspension pour vecteurs retroviraux
AU5312096A (en) Immunoassay using antibodies directed to the reaction product of enzymes used as labels
AU574735B2 (en) Ammonia from synthesis gas
AU4261599A (en) Amphotropic retrovirus packaging cell line, process for its production and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2296319

Country of ref document: CA

Ref country code: CA

Ref document number: 2296319

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998936923

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 85762/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998936923

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936923

Country of ref document: EP